Helius Medical Technologies to Present at LD Micro Invitational XIII 2023
Rhea-AI Summary
Helius Medical Technologies (NASDAQ: HSDT), a neurotech company specializing in therapeutic neuromodulation for balance and gait deficits, has announced its participation in the LD Micro Invitational XIII 2023. The event will take place at the Luxe Sunset Boulevard Hotel in California.
President and CEO Dane Andreeff, along with CFO Jeff Mathiesen, will represent Helius at the conference. Their presentation is scheduled for Wednesday, June 7, 2023, at 4:00 PM PT. Interested parties can access the webcast through the provided link.
Investors and attendees wishing to arrange one-on-one meetings with Helius management are encouraged to contact LD Micro directly. This event provides an opportunity for Helius to showcase its innovative approach to neuromodulation therapy and engage with potential investors.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, HSDT gained 2.50%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Newtown, Pennsylvania--(Newsfile Corp. - May 25, 2023) - Helius Medical Technologies, Inc. (NASDAQ: HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that Dane Andreeff, President and Chief Executive Officer, and Jeff Mathiesen, Chief Financial Officer, will present at LD Micro Invitational XIII 2023, at the Luxe Sunset Boulevard Hotel, California, as follows:
Date: Wednesday, June 7, 2023
Time: 4:00 PM PT
Webcast: Click here
Investors and attendees who would like to schedule a 1-on-1 meeting with Helius management are asked to contact LD Micro.
About Helius Medical Technologies, Inc.
Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using non-implantable platform technologies that amplify the brain's ability to compensate and promotes neuroplasticity, aiming to improve the lives of people dealing with neurologic diseases. The Company's first commercial product is the Portable Neuromodulation Stimulator (PoNS). For more information, visit www.heliusmedical.com.
About the PoNS Device and PoNS Therapy
The Portable Neuromodulation Stimulator (PoNS) is an innovative non-surgical medical device, inclusive of a controller and mouthpiece, which delivers electrical stimulation to the surface of the tongue to improve balance and gait. The PoNS device is indicated for use in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from multiple sclerosis ("MS") and is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only.
PoNS is also authorized for sale in Canada for three indications: (i) for use as a short-term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury ("mmTBI") and is to be used in conjunction with physical therapy; and (ii) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS and is to be used in conjunction with physical therapy; and (iii) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from stroke, to be used in conjunction with physical therapy. PoNS is also authorized for sale in Australia for short term use by healthcare professionals as an adjunct to a therapeutic exercise program to improve balance and gait. For more information visit www.ponstherapy.com.
Investor Relations Contact
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/167368
FAQ
When and where is Helius Medical Technologies (HSDT) presenting at the LD Micro Invitational XIII 2023?
Who will be representing Helius Medical Technologies (HSDT) at the LD Micro Invitational XIII 2023?
How can investors attend Helius Medical Technologies' (HSDT) presentation at the LD Micro Invitational XIII 2023?
What is the focus of Helius Medical Technologies (HSDT) as mentioned in the press release?
